{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:27:01Z","timestamp":1766068021123,"version":"3.37.3"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The activins\u2013follistatins\u2013inhibins (AFI) hormonal system affects bone metabolism. Treatments that alter bone metabolism may also alter the AFI molecules. In this non-randomized, open-label, head-to-head comparative study, circulating levels of the AFI system were evaluated in postmenopausal women with osteoporosis treated for 12\u00a0mo with either teriparatide (n\u2009=\u200923) or denosumab (n\u2009=\u200922). \u03a4eriparatide treatment increased activin B (P=.01) and activin AB (P=.004) and the ratios activin A\/follistatin (P=.006), activin B\/follistatin (P=.007), activin AB\/follistatin (P&amp;lt;.001), and activin AB\/ follistatin-like 3 (FSTL3) (P=.034). The significant P for trend in group \u00d7 time interactions of activins B and AB and of the ratio activin AB\/FSTL3 remained robust after adjustment for BMI and LS BMD but it was lost for activin B after adjustment for previous antiresorptive treatment. The effect of teriparatide on BMD was attenuated when it was adjusted for baseline activins levels or their 12-mo changes. No changes were observed after denosumab treatment. In conclusion, activins B and AB, as well as the ratios of all activins to follistatin and of activin AB to FSTL3 increased with teriparatide treatment, possibly in a compensatory manner. Future studies are needed to study the potentially important role activins may play in bone biology and any associations with the effect of teriparatide on BMD.<\/jats:p>\n               <jats:p>Clinical Trials identifier: NCT04206618. ClinicalTrials.gov \u00a0https:\/\/clinicaltrials.gov\/search?term=NCT04206618.<\/jats:p>","DOI":"10.1093\/jbmr\/zjae106","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T15:03:53Z","timestamp":1720451033000},"page":"1306-1314","source":"Crossref","is-referenced-by-count":4,"title":["The comparative effect of teriparatide and denosumab on activins, follistatins, and inhibins in women with postmenopausal osteoporosis"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9624-6296","authenticated-orcid":false,"given":"Athanasios D","family":"Anastasilakis","sequence":"first","affiliation":[{"name":"424 Military General Hospital Department of Endocrinology, , 56429, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stergios A","family":"Polyzos","sequence":"additional","affiliation":[{"name":"Aristotle University of Thessaloniki First Laboratory of Pharmacology, Medical School, , 54124, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3231-3357","authenticated-orcid":false,"given":"Polyzois","family":"Makras","sequence":"additional","affiliation":[{"name":"251 Hellenic Air Force & VA General Hospital Department of Endocrinology and Diabetes and Department of Medical Research, , 15561, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthaios","family":"Savvidis","sequence":"additional","affiliation":[{"name":"424 Military General Hospital 1 st Department of Orthopedics, , 56429, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos S","family":"Mantzoros","sequence":"additional","affiliation":[{"name":"Boston VA Healthcare System and Beth Israel Deaconess Medical Center Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Harvard Medical School, , 02215, Boston, MA, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"issue":"2","key":"2024090404455531700_ref1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.exger.2012.11.004","article-title":"Effects of the activin A-myostatin-follistatin system on aging bone and muscle progenitor cells","volume":"48","author":"Bowser","year":"2013","journal-title":"Exp Gerontol"},{"issue":"1","key":"2024090404455531700_ref2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1196\/annals.1315.023","article-title":"Activins and inhibins and their signaling","volume":"1038","author":"Vale","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"2024090404455531700_ref3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.metabol.2018.05.003","article-title":"Regulation of the activins-follistatins-inhibins axis by energy status: impact on reproductive function","volume":"85","author":"Perakakis","year":"2018","journal-title":"Metabolism"},{"key":"2024090404455531700_ref4","doi-asserted-by":"crossref","first-page":"155397","DOI":"10.1016\/j.metabol.2022.155397","article-title":"Activins, follistatins and inhibins in postmenopausal osteoporosis: a proof of concept, case-control study","volume":"141","author":"Anastasilakis","year":"2023","journal-title":"Metabolism"},{"issue":"3","key":"2024090404455531700_ref5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s12020-023-03402-x","article-title":"Association of activins, follistatins and inhibins with incident hip fracture in women with postmenopausal osteoporosis: a proof of concept, case-control study","volume":"81","author":"Anastasilakis","year":"2023","journal-title":"Endocrine"},{"issue":"10","key":"2024090404455531700_ref6","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.metabol.2015.07.011","article-title":"Novel therapies for osteoporosis","volume":"64","author":"Makras","year":"2015","journal-title":"Metabolism"},{"issue":"1","key":"2024090404455531700_ref7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11657-019-0584-3","article-title":"The 2018 guidelines for the diagnosis and treatment of osteoporosis in Greece","volume":"14","author":"Makras","year":"2019","journal-title":"Arch Osteoporos"},{"issue":"24","key":"2024090404455531700_ref8","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1242\/jcs.114.24.4359","article-title":"Smad regulation in TGF-beta signal transduction","volume":"114","author":"Moustakas","year":"2001","journal-title":"J Cell Sci"},{"issue":"2","key":"2024090404455531700_ref9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2174\/1874467211205020195","article-title":"Activin receptor signaling: a potential therapeutic target for osteoporosis","volume":"5","author":"Lotinun","year":"2012","journal-title":"Curr Mol Pharmacol"},{"issue":"5","key":"2024090404455531700_ref10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ng1783","article-title":"A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva","volume":"38","author":"Shore","year":"2006","journal-title":"Nat Genet"},{"issue":"7","key":"2024090404455531700_ref11","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1007\/s00198-012-2198-0","article-title":"Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment","volume":"24","author":"Anastasilakis","year":"2013","journal-title":"Osteoporos Int"},{"issue":"1","key":"2024090404455531700_ref12","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/stem.2924","article-title":"mDia1 and Cdc42 regulate activin B-induced migration of bone marrow-derived mesenchymal stromal cells","volume":"37","author":"Wang","year":"2019","journal-title":"Stem Cells"},{"issue":"1","key":"2024090404455531700_ref13","doi-asserted-by":"crossref","first-page":"E157","DOI":"10.1152\/ajpendo.00193.2009","article-title":"Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin","volume":"297","author":"Gilson","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"10","key":"2024090404455531700_ref14","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.metabol.2016.07.002","article-title":"Circulating follistatin displays a day-night rhythm and is associated with muscle mass and circulating leptin levels in healthy, young humans","volume":"65","author":"Anastasilakis","year":"2016","journal-title":"Metabolism"},{"issue":"33","key":"2024090404455531700_ref15","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111401118","article-title":"Local versus systemic control of bone and skeletal muscle mass by components of the transforming growth factor-beta signaling pathway","volume":"118","author":"Liu","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2024090404455531700_ref16","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1096\/fj.201801969RR","article-title":"A follistatin-based molecule increases muscle and bone mass without affecting the red blood cell count in mice","volume":"33","author":"Lodberg","year":"2019","journal-title":"FASEB J"},{"key":"2024090404455531700_ref17","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bone.2015.04.038","article-title":"Follistatin-like 3 is a mediator of exercise-driven bone formation and strengthening","volume":"78","author":"Nam","year":"2015","journal-title":"Bone"},{"key":"2024090404455531700_ref18","doi-asserted-by":"crossref","first-page":"115692","DOI":"10.1016\/j.bone.2020.115692","article-title":"Activin type IIA decoy receptor and intermittent parathyroid hormone in combination overturns the bone loss in disuse-osteopenic mice","volume":"142","author":"Brent","year":"2021","journal-title":"Bone"},{"issue":"11","key":"2024090404455531700_ref19","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1096\/fj.07-8080com","article-title":"The activin A-follistatin system: potent regulator of human extracellular matrix mineralization","volume":"21","author":"Eijken","year":"2007","journal-title":"FASEB J"},{"issue":"2","key":"2024090404455531700_ref20","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/rheumatology\/keaa755","article-title":"Osteosarcopenia: where osteoporosis and sarcopenia collide","volume":"60","author":"Clynes","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"2024090404455531700_ref21","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1172\/JCI125915","article-title":"RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass","volume":"129","author":"Bonnet","year":"2019","journal-title":"J Clin Invest"},{"issue":"12","key":"2024090404455531700_ref22","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1111\/jgs.16165","article-title":"Effect of denosumab on falls, muscle strength, and function in community-dwelling older adults","volume":"67","author":"Phu","year":"2019","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"2024090404455531700_ref23","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1007\/s00198-022-06470-3","article-title":"Beneficial effects of denosumab on muscle performance in patients with low BMD: a retrospective, propensity score-matched study","volume":"33","author":"Rupp","year":"2022","journal-title":"Osteoporos Int"},{"issue":"2","key":"2024090404455531700_ref24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4235\/agmr.23.0039","article-title":"Does denosumab really improve muscle strength? Current evidence is weak","volume":"27","author":"Beck","year":"2023","journal-title":"Ann Geriatr Med Res"},{"key":"2024090404455531700_ref25","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgae003","article-title":"Cardiometabolic effects of denosumab in premenopausal women with breast cancer receiving estradiol suppression: RCT","author":"Ramchand","year":"2024","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjae106\/58679095\/zjae106.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/39\/9\/1306\/58994125\/zjae106.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/39\/9\/1306\/58994125\/zjae106.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T11:26:32Z","timestamp":1725449192000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/39\/9\/1306\/7709288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,7,8]]},"published-print":{"date-parts":[[2024,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjae106","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"type":"print","value":"0884-0431"},{"type":"electronic","value":"1523-4681"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,7,8]]}}}